Golimumab for the Treatment of Rheumatoid Arthritis: A Narrative Review of Pivotal Randomized Trials and Real-World Studies
Uta Kiltz, Yi-Ming Chen, Andrea Rubbert-Roth, Sergio Fonseca, José Antunes, Arun Singh, Richard Milek, Jordan Wu, Jeffrey A. Sparks · 2026
Read Golimumab for the Treatment of Rheumatoid Arthritis: A Narrative Review of Pivotal Randomized Trials and Real-World Studies by Uta Kiltz, Yi-Ming Chen, Andrea Rubbert-Roth, Sergio Fonseca, José Antunes, Arun Singh, Richard Milek, Jordan Wu, Jeffrey A. Sparks (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13407820.txt.
Description
Uta Kiltz and co-authors review golimumab for rheumatoid arthritis, in a 2026 narrative review. The disease is a chronic inflammatory autoimmune condition that slowly wears the joints down, year by year. It cuts quality of life, work productivity, and daily function, and it brings pain, fatigue, and structural damage to the joints.
Golimumab blocks tumor necrosis factor, one of the inflammatory cytokines that drive the disease. The review draws on the large randomized trials and on studies of real-world care as it is lived day to day. Set side by side, trial efficacy and real-world performance help rheumatologists judge where this long-used biologic still fits among newer options, and for whom it still earns its place.
Catalog record
| CREATOR | Uta Kiltz, Yi-Ming Chen, Andrea Rubbert-Roth, Sergio Fonseca, José Antunes, Arun Singh, Richard Milek, Jordan Wu, Jeffrey A. Sparks |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 110 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |